Hunt Globally: Wide Search AI Agents for Drug Asset Scouting in Investing, Business Development, and Competitive Intelligence

ArXi:2602.15019v3 Announce Type: replace Bio-pharmaceutical innovation has shifted: many new drug assets now originate outside the United States and are disclosed primarily via regional, non-English channels. Recent data suggests that over 85% of patent filings originate outside the U. S., with China accounting for nearly half of the global total. A growing share of scholarly output is also non-U. S. Industry estimates put China at 30% of global drug development, spanning 1,200+ novel candidates.